Hyperthyroxinemia: Clinical Trials

2 trials for Hyperthyroxinemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Completed 1

Follow Hyperthyroxinemia: new trials by email Literature Review of Hyperthyroxinemia trials Research Report on Hyperthyroxinemia

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Resmetirom - Non-Alcoholic Fatty Liver Disease
Phase 3Active not recruitingMadrigal Pharmaceuticals, Inc.8102021-07-092026-05-27
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Placebo, Resmetirom - Non-Alcoholic Fatty Liver Disease
Phase 3CompletedMadrigal Pharmaceuticals, Inc.13432019-12-162023-09-05

Narrower conditions

Dyslipidemias (2)  ·  Fibrosis (2)  ·  Hyperlipidemias (2)  ·  Non-alcoholic Fatty Liver Disease (2)  ·  Thyroid Hormone Resistance Syndrome (2)

Broader conditions

Digestive System Diseases (2)  ·  Endocrine System Diseases (2)  ·  Fatty Liver (2)  ·  Lipid Metabolism Disorders (2)  ·  Liver Diseases (2)  ·  Metabolic Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Thyroid Diseases (2)

Interventions

resmetirom (2)

Sponsors

Madrigal Pharmaceuticals, Inc. (2)

Countries

Puerto Rico (2)  ·  United States (2)

Top investigators

Rebecca Taub, MD (1)  ·  Tom Hare, MD (1)

Results publications

PMID 37786277, PMID 37845512, PMID 41142528, PMID 41953252